Impact BioMedical Inc Announces Reverse Stock Split for Merger with Zoar Ltd

HOUSTON, Sept. 11, 2026 /CourierPR/ -- Impact BioMedical Inc, a biopharmaceutical company listed on the NYSE American Exchange, is set to undergo a significant corporate restructuring. The company has announced a 1 for 12.62 reverse stock split, effective on September 23, 2026. This move is part of the company’s strategic plan to support the completion of a merger with Zoar Ltd, a global pharmaceutical company with expertise in active pharmaceutical ingredients and contract development and manufacturing services.

The reverse stock split, approved by the Company’s Board of Directors, is intended to streamline the company’s share structure and potentially enhance its stock price. The split will combine every 12.62 shares of Impact BioMedical Inc’s common stock into one share. No fractional shares will be issued, and stockholders who would otherwise receive a fractional share will have their shares rounded up to the nearest whole share.

Impact BioMedical Inc’s Chief Executive Officer, in consultation with the Board, has the discretion to implement a second reverse stock split of the company’s common stock at a ratio of not less than 1-for-12.48 and not more than 1-for-50. This flexibility is aimed at further optimizing the company’s share structure to align with its strategic objectives.

Upon the completion of the proposed merger with Zoar Ltd, the new company will leverage the combined expertise of both organizations. The merger is expected to result in a company with a broad spectrum of active pharmaceutical ingredients and intermediates, focusing on life-saving drugs, particularly in emerging markets. Additionally, the new entity will benefit from significant intellectual property, with potential applications in human health and wellness markets.

Impact BioMedical Inc’s stockholders are expected to receive one share of Zoar Ltd for every four shares of Impact BioMedical Inc held immediately prior to the effective time of the merger, after the reverse stock split. This transaction is subject to approval and is expected to significantly enhance the company’s global presence and capabilities in the pharmaceutical industry.

The reverse stock split will affect all stockholders uniformly, with no alteration to any stockholder’s percentage ownership interest in the company. The total number of shares of common stock outstanding is expected to decrease from approximately 107,821,231 to 8,543,679, subject to minor adjustments due to rounding. Corresponding proportional adjustments will be made to outstanding equity awards, shares available under equity incentive plans, and other relevant share-based agreements.

Equiniti Trust Company, LLC, the company’s transfer agent, will manage the exchange of shares for stockholders. Unless a stockholder specifically requests new paper certificates, new shares will be issued electronically in book-entry form. The reverse stock split will not affect the total number of authorized shares, and all resulting shares will remain fully paid and non-assessable.